ACCC claims Nurofen fine an ‘inadequate deterrent’, appeals decision

May 23, 2016 4:46

Despite court orders interim packaging allows Nurofen to highlight specific pain relief

The consumer watchdog has called a $1.7m fine against Reckitt Benckiser as inadequate after the company was found to be using false and misleading marketing on products claiming to target specific pain.

The Australian Competition and Consumer Commission (ACCC) will seek to appeal the Federal Court decision handed down last year after it challenged the truthfulness of pain relieving medications that claim to be able to target specific pain, such as migraines, back pain, period pain and tension headache.

The court found all four pain relievers contained the same active ingredient and could not target pain specifically or any differently from each other.

Subscribe to keep reading

Your daily source for the latest headlines, in-depth analysis, and breaking stories from around the globe.

Simon Canning

Simon Canning was Mumbrella's marketing and advertising editor from 2015-2017. In a career spanning journalism and communications over more than 30 years Simon has become one of Australia’s most respected analysts and commentators on the advertising, marketing and media industries. A regular commentator on radio and TV, Simon has also worked in media in the US and UK .

Topics